First-quarter results of pharma bigwigs like Pfizer PFE, Merck MRK and Allergan AGN stole the limelight this week. Other than that, Novartis NVS gained FDA approval for the second indication of its CAR-T therapy, Kymriah. While AbbVie ABBV submitted a ...
Yahoo! · 1mon
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center are highlighting two trades on Pfizer (PFE) today after it closed ... as long as the stock closes above $34 at expiration.
AZN stock was down $7.28, or 9.07%, in pre-market trading. YTD, the stock is up 37.07%. PFE stock was up 38 cents, or 1.3%, in pre-market trading. YTD, the stock is down 4.4%. Shares of AstraZeneca (AZN) offer a dividend yield of 3.49% based on Friday’s ...
Dividend.com · 1mon
And despite issuing better-than-predicted 2018 guidance, PFE stock fell as much as 2 percent in early morning trading. Heading into the earnings report, Pfizer shares were up 24 percent, matching the gains of the Standard & Poor's 500 index. Here's a ...
The Dow endured a particularly tough week, ending with marginal gains for the first time only on Thursday. During the early half of the week, strong earnings results failed to boost investor sentiment. Trade and inflation related fears weighed on investors ...
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) reported fourth-quarter earnings Tuesday morning, marginally exceeding earnings expectations and meeting expected revenue numbers. And despite issuing better-than-predicted 2018 guidance, PFE stock fell as much ...
Finance Yahoo · 4mon